Oncology: State-of-the-Art Researches in Poland

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: 29 November 2024 | Viewed by 1926

Special Issue Editors


E-Mail Website
Guest Editor
Department of Clinical Genetics, Medical University of Lodz, 90-419 Lodz, Poland
Interests: bladder cancer; genetic markers; heterogeneity of cancers; liquid biopsy; NGS; artificial intelligence

E-Mail Website
Guest Editor
Department of Chemotherapy, Medical University of Lodz, Copernicus Memorial Hospital of Lodz, 93-513 Lodz, Poland
Interests: hormonal drugs; chemotherapy; cancer; oncology

Special Issue Information

Dear Colleagues,

In recent decades, significant progress in the field of cancer therapy has been achieved. Despite this, tumor response to treatment is still suboptimal. This is partly due to the failure to identify subgroups of patients who may benefit most from a particular therapy. Therefore, efforts to identify such subgroups and to search for new markers are still challenging.

In this Special Issue, we aim to showcase state-of-the-art research in oncology in Poland. We invite submissions looking at all kinds of research covering all cancer types and stages, from basic laboratory research to translational and clinical research, including cohort studies, randomized controlled trials, and epidemiological studies. Submitting a paper to this Special Issue of Cancers is a good opportunity to contribute to the international visibility of the important efforts carried out by large and small cancer research groups throughout the different Polish research centers, universities, and other academic and research institutions.

Dr. Edyta Marta Borkowska
Dr. Piotr Potemski
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • oncology
  • biomarkers
  • personalized treatment
  • Poland

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

19 pages, 8215 KiB  
Article
ONCOBREAST-TEST Is a Quick Diagnostic, Prognostic and Predictive Method of Response to Systemic Treatment
by Anna Tankiewicz-Kwedlo, Tomasz Lobacz, Leszek Kozlowski, Bogumila Czartoryska-Arlukowicz, Mariusz Koda, Krystyna Pawlak, Robert Czarnomysy, Magdalena Joanna Borkowska and Dariusz Pawlak
Cancers 2024, 16(1), 120; https://doi.org/10.3390/cancers16010120 - 26 Dec 2023
Viewed by 860
Abstract
ONCOBREAST-TEST is a diagnostic and therapeutic procedure that is part of the comprehensive care of a patient with breast cancer.: Chemosensitivity of cancer cells was assessed using the MTT test, morphological assessment of cells, LDH activity in the culture medium, and flow cytometry [...] Read more.
ONCOBREAST-TEST is a diagnostic and therapeutic procedure that is part of the comprehensive care of a patient with breast cancer.: Chemosensitivity of cancer cells was assessed using the MTT test, morphological assessment of cells, LDH activity in the culture medium, and flow cytometry technique (apoptosis, proliferation, CD24, CD44, GATA3, cytokeratin, Ki-67). Diagnostic tools included panels of simple tests which could be used to accurately predict the chemosensitivity of tumor cells previously isolated from a patient, even before actual chemotherapy. The proposed procedure allows for a simple (based on MTT results, cell morphology, LDH concentration), minimally invasive, quick, and accurate assessment of the sensitivity of breast cancer cells to the drugs used and, to select the most effective treatment plan as part of personalized therapy. In a patient with NOS G3, the most promising therapy will be docetaxel with cyclophosphamide and in the case of a patient with NOS G1, paclitaxel alone and in combination with trastuzumab. The implementation of such a procedure would undoubtedly increase the effectiveness of chemotherapy, reduce side effects by excluding drugs that are ineffective before using them, protect the patient’s health, and shorten the treatment time, bringing economic and social benefits. Full article
(This article belongs to the Special Issue Oncology: State-of-the-Art Researches in Poland)
Show Figures

Figure 1

15 pages, 3499 KiB  
Article
CD4, CD20 and PD-L1 as Markers of Recurrence in Non-Muscle-Invasive Bladder Cancer
by Aleksandra Semeniuk-Wojtaś, Magdalena Modzelewska, Karolina Poddębniak-Strama, Sylwia Kołaczyńska, Arkadiusz Lubas, Barbara Górnicka, Anna Jakieła and Rafał Stec
Cancers 2023, 15(23), 5529; https://doi.org/10.3390/cancers15235529 - 22 Nov 2023
Cited by 2 | Viewed by 778
Abstract
Introduction: A tumor microenvironment plays an important role in bladder cancer development and in treatment response. Purpose: The aim of the study was to assess how the components of the microenvironment affect tumor recurrence and to find the potential biomarkers for immunotherapy in [...] Read more.
Introduction: A tumor microenvironment plays an important role in bladder cancer development and in treatment response. Purpose: The aim of the study was to assess how the components of the microenvironment affect tumor recurrence and to find the potential biomarkers for immunotherapy in NMIBC. Methods: The study group consisted of 55 patients with primary NMIBC. Immunohistochemistry was performed on sections of primary papillary urothelial carcinoma of the bladder. Cox proportional hazard multiple regression analysis was performed to characterize tumors with the highest probability of an unfavorable outcome. Results: Multivariate analysis confirmed that the CD4 (p = 0.001), CD20 (p = 0.008) and PD-L1 expressed on tumor cells (p = 0.01) were independently associated with the risk of recurrence of bladder cancer. Patients with weak CD4+ cell infiltration (<4.6%) and severe CD20+ infiltration (>10%) belong to the group with a lower risk of recurrence. The cancer in this group also frequently recurs after 12 months (p = 0.0005). Conclusions: The evaluation of CD4+ and CD20+ cells in the tumor microenvironment, in addition to PD-L1 on tumor cells, facilitates the determination of a group of patients with a low risk of recurrence. Full article
(This article belongs to the Special Issue Oncology: State-of-the-Art Researches in Poland)
Show Figures

Figure 1

Back to TopTop